Skip to main content

Table 2 Plasma concentrations of ABT-116, carprofen, tramadol, and placebo before and after the first and last doses of the treatment period

From: Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis

Treatment group

Trial day 8

Trial day 22

 

Before dosing

3 hours after dosing

n

Before dosing

3 hours after dosing

n

ABT-116

0 ± 0

569 ± 294

12#

1,277 ± 644

1,589 ± 700***

12#

ABT-116 metabolite

0 ± 0

115 ± 63

11#

592 ± 256

538 ± 244***

11#

Carprofen

0 ± 0

3,386 ± 2,282

11#

3,752 ± 2,211

4,779 ± 2,789

11#

Tramadol

0.0 ± 0.0

39.3 ± 35.3

11#

0.6 ± 1.9

7.1 ± 8.8**

11#

  1. Note: All values represent mean ± standard deviation in ng/ml. n – sample number. #One dog in the treatment group was excluded because high drug concentrations were detected in the pre-treatment sample and low concentrations in one or more post-treatment samples. ABT-116, Carprofen, and Tramadol were not detected in any plasma sample from the Placebo group. Significance of changes in plasma drug concentrations from post-treatment sample on Day 8 is indicated as follows: ** - P < 0.01; *** - P < 0.001.